ALVR vs. ATRA, BLUE, AVXL, STRO, MGTX, TNYA, SOPH, AGEN, REPL, and SLDB
Should you be buying AlloVir stock or one of its competitors? The main competitors of AlloVir include Atara Biotherapeutics (ATRA), bluebird bio (BLUE), Anavex Life Sciences (AVXL), Sutro Biopharma (STRO), MeiraGTx (MGTX), Tenaya Therapeutics (TNYA), SOPHiA GENETICS (SOPH), Agenus (AGEN), Replimune Group (REPL), and Solid Biosciences (SLDB). These companies are all part of the "biological products, except diagnostic" industry.
Atara Biotherapeutics (NASDAQ:ATRA) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, community ranking, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.
AlloVir has lower revenue, but higher earnings than Atara Biotherapeutics. AlloVir is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Atara Biotherapeutics has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.
70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 3.7% of Atara Biotherapeutics shares are held by insiders. Comparatively, 33.9% of AlloVir shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Atara Biotherapeutics presently has a consensus target price of $28.00, indicating a potential upside of 4,891.98%. AlloVir has a consensus target price of $18.50, indicating a potential upside of 2,350.66%. Given AlloVir's stronger consensus rating and higher probable upside, analysts clearly believe Atara Biotherapeutics is more favorable than AlloVir.
In the previous week, Atara Biotherapeutics had 2 more articles in the media than AlloVir. MarketBeat recorded 4 mentions for Atara Biotherapeutics and 2 mentions for AlloVir. Atara Biotherapeutics' average media sentiment score of 1.44 beat AlloVir's score of 0.99 indicating that AlloVir is being referred to more favorably in the news media.
AlloVir has a net margin of 0.00% compared to AlloVir's net margin of -671.70%. Atara Biotherapeutics' return on equity of -98.50% beat AlloVir's return on equity.
Atara Biotherapeutics received 402 more outperform votes than AlloVir when rated by MarketBeat users. Likewise, 67.56% of users gave Atara Biotherapeutics an outperform vote while only 57.45% of users gave AlloVir an outperform vote.
Summary
AlloVir beats Atara Biotherapeutics on 9 of the 17 factors compared between the two stocks.
Get AlloVir News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
